Google Searches for GLP-1 Drugs Like Ozempic Are Massively Outstripping Traditional Weight Loss Searches
This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
For those who've witnessed the massive surge in interest in the GLP-1 phenomenon this year, it would most certainly not come as a surprise that this new class of drugs is now a titan among the more traditional weight loss methods, at least as far as Google searches are concerned.
Glucagon-Like Peptide-1 (GLP-1) hormone plays an important role in regulating hunger by stimulating the release of insulin in the pancreas, blocking the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slowing the emptying of the stomach to reduce the overall food intake. Simultaneously, GLP-1 receptors also suppress the brain's stress response and reward/reinforcement mechanism to increase the feeling of satiation.
Looks like $GPCR missed the mark - we anticipated 7-10% weight loss needed to match $LLY (vs. 3% shown) and minimized AEs (GPCR seems to have hit on this with only 1 discontinue in the T2D group and none in obesity group)
Oral GLP proving to be tricky....is there really a window… https://t.co/O7AagQLLiP pic.twitter.com/cFLf9cUbzK
— BowTiedBiotech
Read more on wccftech.com
